Shares of UroGen Pharma URGN were unchanged after the company reported Q3 results.
Quarterly Results
Earnings per share were down 23.58% over the past year to ($1.31), which beat the estimate of ($1.49).
Revenue of $3,461,000 up by 0.00% year over year, which beat the estimate of $3,340,000.
Guidance
UroGen Pharma hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: Nov 09, 2020
Time: 08:30 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/gh8p8meu
Recent Stock Performance
Company's 52-week high was at $35.21
52-week low: $13.12
Price action over last quarter: down 1.98%
Company Profile
UroGen Pharma Ltd is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. It has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. The company's lead product candidates, UGN-101 and UGN-102, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
